Certified by Founder
Lodge
smartbax
start up
Germany
- München
- 24/05/2023
- Seed
- $1,291,000
smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
- Industry Biotechnology Research
- Website https://www.smartbax.de/
- LinkedIn https://www.linkedin.com/company/smartbax-gmbh/
Iceotope | $26,000,000 | (May 15, 2026)
Harken Sweets | Undisclosed Amount | (May 15, 2026)
Graphon AI | $8,300,000 | (May 15, 2026)
Ranger AI | $8,400,000 | (May 15, 2026)
Wirestock | $23,000,000 | (May 15, 2026)
GridCARE | $64,000,000 | (May 15, 2026)
Chromie Health | $2,000,000 | (May 15, 2026)
Novella | $21,000,000 | (May 15, 2026)
Flick | $6,000,000 | (May 15, 2026)
Synthetic | $10,000,000 | (May 14, 2026)
SwishX | $2,200,000 | (May 14, 2026)
Urologic Health | $11,000,000 | (May 14, 2026)